Indeed, not soon after the approval of Zoetis’ interleukin 31 (IL-31)-targeting antibody Cytopoint (lokivetmab) to treat atopic dermatitis in dogs, Galderma and Chugai Pharmaceutical agreed to ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals 12 years and older with eczema that is not sufficiently controlled with ...